*To the Editor*:

Angiotensin-converting enzyme 2 (ACE2) has been identified as the cell entry receptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \[[@C1], [@C2]\]. Importantly, smokers and patients with COPD are at an increased risk of severe complications and a higher mortality upon SARS-CoV-2 infection \[[@C3]\]. We hypothesised that ACE2 expression is increased in lungs of smokers and patients with COPD, which may at least partially explain their higher risk of a more severe course of coronavirus disease 2019 (COVID-19). Therefore, we aimed to investigate the expression of ACE2 on both mRNA and protein level in a large number of lung tissue specimens of well-phenotyped subjects, including never-smokers, current smokers without airflow limitation, and patients with COPD.

In this cross-sectional observational study, we analysed lung tissue specimens from 134 subjects from our large lung tissue biobank at Ghent University Hospital (Ghent, Belgium) and from explant lungs from end-stage COPD patients collected at UZ Gasthuisberg Leuven (Leuven, Belgium). Ex-smoking was defined as smoking cessation for ≥1 year. COPD severity was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. Written informed consent was obtained from all subjects, and the study was approved by the medical ethical committees of Ghent University Hospital (2016/0132; 2019/0537) and the University Hospital Gasthuisberg Leuven (S51577).

RNA extraction from lung tissue blocks of 120 subjects was performed with the miRNeasy Mini kit (Qiagen, Hilden, Germany). Next, cDNA was prepared with the EvoScript Universal cDNA Master Kit (Roche, Basel, Switzerland), followed by reverse transcriptase (RT)-qPCR analysis for ACE2 and 3 reference genes, as described previously \[[@C4], [@C5]\].

Sections from formalin-fixed paraffin-embedded lung tissue blocks of 87 subjects were stained for ACE2. After antigen retrieval with citrate buffer (Scytek, West Logan, UT, USA), the slides were incubated with anti-ACE2 antibody (polyclonal rabbit-anti-human, Abcam ab15248). Next, slides were coloured with diaminobenzidine (Dako, Carpinteria, CA, USA) and counterstained with Mayer\'s haematoxylin (Sigma-Aldrich, St Louis, MO, USA). Quantitative measurements of the ACE2-positive signal in alveolar tissue and bronchial epithelium were performed on images of stained paraffin sections as described previously \[[@C6]\].

Statistical analysis was performed using Sigma Stat software (SPSS 26.0, Chicago, IL, USA) and R3.5.1, using Kruskal--Wallis tests (on all six groups) followed by Mann--Whitney U-tests (for the comparison between two groups), and multivariable linear regression analyses.

Using RT-PCR, ACE2 mRNA levels were determined in lung tissue from 120 subjects. ACE2 mRNA expression was significantly higher in the lung tissue of current smokers without airflow limitation and current smokers with COPD (GOLD stages II and III--IV) compared with never-smokers ([figure 1a](#F1){ref-type="fig"}). In addition, ex-smokers without airflow limitation showed significantly lower ACE2 mRNA levels, compared with current smokers. Multivariable linear regression analysis demonstrated that current smoking and COPD are both independently associated with increased ACE2 mRNA expression in lung tissue, even after adjustment for covariates, including age, sex, body mass index and arterial hypertension (data not shown).

![Gene and protein expression of angiotensin-converting enzyme 2 (ACE2) in the airways and lungs. a) ACE2 mRNA expression is increased in the lung tissue of smokers and COPD subjects. ACE2 mRNA expression in the lung tissue of never-, current and ex-smokers without airflow limitation and current and ex-smokers with moderate (Global Initiative of Chronic Obstructive Lung Disease (GOLD) stage II) or severe-to-very severe (GOLD stage III--IV) COPD, normalised to the expression of the housekeeping controls glyceraldehyde-3-phosphate dehydrogenase, peptidylprolyl isomerase A and succinate dehydrogenase complex flavoprotein subunit A. b) ACE2 protein levels are increased in the alveolar tissue of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical staining in the alveolar tissue of never-smokers, smokers without airflow limitation, smokers with COPD GOLD stage II and smokers with COPD GOLD stage III--IV. The area of ACE2-positive signal was normalised to the total area of alveolar tissue present in each analysed image. c) ACE2 protein levels are increased in the bronchial epithelium of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical staining in the bronchial epithelium of never-smokers, smokers without airflow limitation and smokers with COPD (GOLD stages II and III--IV). The area of ACE2-positive signal in each airway was normalised to the length of the basement membrane (Pbm). Data are presented as means±[sem]{.smallcaps}. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](ERJ-02378-2020.01){#F1}

Through immunohistochemical (IHC) staining, ACE2 protein levels were assessed in lung tissue from 87 subjects. ACE2 IHC revealed positive staining in both bronchial and alveolar epithelial cells, with the latter predominantly in alveolar type II cells ([figure 1b](#F1){ref-type="fig"} and c). Quantification of ACE2 protein levels in the alveolar tissue revealed a significantly higher percentage of ACE2-positive alveolar tissue in current smokers without airflow limitation and current smokers with COPD (GOLD stages II and III--IV) compared with never-smokers ([figure 1b](#F1){ref-type="fig"}). Moreover, the percentage of ACE2-positive alveolar tissue was significantly higher in patients with COPD GOLD stage III--IV, compared with ex-smokers without airflow limitation and ex-smokers with COPD GOLD stage II ([figure 1b](#F1){ref-type="fig"}). Quantification of ACE2 staining in the bronchial epithelium revealed numerically higher levels in current smokers without airflow limitation and current smokers with COPD GOLD stage II, and significantly higher levels in patients with COPD GOLD stage III--IV, compared with never-smokers ([figure 1c](#F1){ref-type="fig"}). Moreover, ACE2 protein levels in the bronchial epithelium were significantly higher in patients with COPD GOLD stage III--IV, compared with ex-smokers without airflow limitation and ex-smokers with COPD GOLD stage II ([figure 1c](#F1){ref-type="fig"}). The observed association between COPD and ACE2 protein expression in alveolar tissue or bronchial epithelium remained significant after adjustment for possible confounders (data not shown).

As healthcare systems around the world are currently under great pressure due to the COVID-19 outbreak, identification of those at high risk is crucial. There is compelling evidence of a more severe course of COVID-19 in smokers and patients with comorbidities such as COPD. We clearly demonstrate an increased pulmonary expression of the SARS-CoV-2 entry receptor ACE2 in smokers and COPD subjects at both mRNA and protein level. While our observations complement previous reports on increased ACE2 mRNA and protein levels in whole lung tissue and bronchial epithelium \[[@C7]--[@C10]\], this is the first study demonstrating increased ACE2 protein in the alveolar epithelium of smokers and patients with COPD, which can be directly linked to the site of injury when patients with severe COVID-19 develop dyspnoea, hypoxia and pneumonia.

Currently, published data on COVID-19 in patients with COPD is fairly limited \[[@C11]\]. Nevertheless, an increased risk of developing severe COVID-19 as well as a higher mortality, has been reported in patients with COPD and in current smokers \[[@C3], [@C12]\]. Although there are several possible explanations for the increased susceptibility of severe COVID-19 in patients with COPD, including older age, comorbidities, dysregulated immune defences and impaired mucociliary clearance, increased pulmonary expression of the SARS-CoV-2 entry receptor ACE2 is most likely another contributor \[[@C13]\]. Importantly, it has been demonstrated in mouse models that transgenic (over)expression of human ACE2 enhances the pathogenicity of SARS-CoV-1 and SARS-CoV-2 \[[@C14]\]. Moreover, human ACE2 was essential for viral replication in the lung.

The main strength of this study is the large number of lung tissue samples from well-phenotyped subjects that are included in the RT-PCR and IHC analyses. Moreover, IHC allowed us to quantify ACE2 protein levels in both bronchial and alveolar epithelium. However, certain limitations should be kept in mind. First, this study consists mainly of samples from lung resections for pulmonary tumours. This may introduce selection bias, as altered expression of ACE2 in lung cancer has been suggested \[[@C15]\]. Secondly, samples of (very) severe COPD originate from a different patient population (lung transplantation), for which smoking cessation was an inclusion criterium. Finally, as we did not study lung tissue samples from COVID-19-positive subjects, we can only speculate on the importance of increased ACE2 in the pathogenicity of SARS-CoV-2.

In conclusion, we report higher ACE2 mRNA and protein levels in lung tissue of smokers and subjects with moderate-to-(very)-severe COPD. Importantly, ACE2 protein levels are not only increased in bronchial but also in alveolar epithelium. Further research is needed to elucidate whether upregulation of ACE2 expression in airways and lungs has consequences for the infectivity and clinical outcome of COVID-19.
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